Related content

Gamma-irradiation induces HER-2/ neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab

By Voutsas Ioannis F.  

International Journal of Radiation Biology, Vol. 89, Iss. 5, 2013-05 ,pp. : 319-325

Informa Healthcare

Access to resources Recommend Favorite

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

By Kerklaan Bojana   Diéras Veronique   Tourneau Christophe   Mergui-Roelvink Marja   Huitema Alwin   Rosing Hilde   Beijnen Jos   Marreaud Sandrine   Govaerts Anne-Sophie   Piccart-Gebhart Martine   Schellens Jan   Awada Ahmad  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 53-62

Springer Publishing Company

Access to resources Recommend Favorite

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

By Venturini M.   Bighin C.   Monfardini S.   Cappuzzo F.   Olmeo N.   Durando A.   Puglisi F.   Nicoletto O.   Lambiase A.   Mastro L.  

Breast Cancer Research and Treatment, Vol. 95, Iss. 1, 2006-01 ,pp. : 45-53

Springer Publishing Company

Access to resources Recommend Favorite

Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer

By Gillogly Michael   Kallinteris Nikoletta   Xu Minzhen   Gulfo Joseph   Humphreys Robert   Murray James  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 6, 2004-06 ,pp. : 490-496

Springer Publishing Company

Access to resources Recommend Favorite